Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism

(NASDAQ:TVTX) SAN DIEGO--(BUSINESS WIRE)---- $TVTX #ICIEM2025--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company shared two oral presentations in classical homocystinuria (HCU) at the International Congress of Inborn Errors of Metabolism, taking place September 2-6 in Kyoto, Japan. New long-term data from Cohort 6 of the Phase 1/2 COMPOSE open-label extension (OLE) Study demonstrated that at the target dose of 2.5 mg/kg twice weekly, participants treated with pegtibatinase in the OLE maintained signific